Pasithea Positive In Vivo Preclinical Efficacy Data in Cancer Xenograft Models

 -- Preclinical data continues to demonstrate PAS-004’s potentially superior properties as compared to FDA approved MEK inhibitors --

-- Once daily dose of PAS-004 delivers anti-tumor efficacy in in vivo NRAS mutation cancer models --

https://www.globenewswire.com/news-release/2023/12/11/2793833/0/en/Pasithea-Therapeutics-Announces-Positive-In-Vivo-Preclinical-Efficacy-Data-for-PAS-004-from-NRAS-Mutation-Cancer-Xenograft-Models.html